CellaVision AB (publ) CLVSF Stock
CellaVision AB (publ) Price Chart
CellaVision AB (publ) CLVSF Financial and Trading Overview
| CellaVision AB (publ) stock price | 13.49 USD |
| Previous Close | 13.49 USD |
| Open | 15 USD |
| Bid | 12.6 USD x 10000 |
| Ask | 13.38 USD x 10000 |
| Day's Range | 13.49 - 15 USD |
| 52 Week Range | 13.49 - 19.28 USD |
| Volume | 400 USD |
| Avg. Volume | 38 USD |
| Market Cap | 321.76M USD |
| Beta (5Y Monthly) | 0.955 |
| PE Ratio (TTM) | 22.483332 |
| EPS (TTM) | 0.61 USD |
| Forward Dividend & Yield | 0.3 (2.19%) |
| Ex-Dividend Date | April 29, 2026 |
| 1y Target Est | N/A |
CLVSF Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | 22.483332 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.37787113 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
CellaVision AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.955 |
| 52-Week Change | -30.029% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 19.28 USD |
| 52 Week Low | 13.49 USD |
| 50-Day Moving Average | 14.81 USD |
| 200-Day Moving Average | 16.89 USD |
CLVSF Share Statistics
| Avg. Volume (3 month) | 38 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 23.85M |
| Float | 19.56M |
| Short Ratio | N/A |
| % Held by Insiders | 16.91% |
| % Held by Institutions | 74.25% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.4448 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 18.35% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 67.98% |
| EBITDA Margin | 26.57% |
Management Effectiveness
| Return on Assets (ttm) | 9.95% |
| Return on Equity (ttm) | 15.29% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | -14.59% |
| Gross Profit (ttm) | N/A |
| EBITDA | 194.13M USD |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | 0.6 |
| Quarterly Earnings Growth (yoy) | -45.80% |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | 2.45 USD |
| Current Ratio (mrq) | 3.802 |
| Book Value Per Share (mrq) | 35.7 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | 89.92M USD |
Profile of CellaVision AB (publ)
| Country | United States |
| State | N/A |
| City | Lund |
| Address | MobilvAegen 12 |
| ZIP | 223 62 |
| Phone | 46 4 64 60 16 00 |
| Website | https://www.cellavision.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 241 |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
Q&A For CellaVision AB (publ) Stock
What is a current CLVSF stock price?
CellaVision AB (publ) CLVSF stock price today per share is 13.49 USD.
How to purchase CellaVision AB (publ) stock?
You can buy CLVSF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CellaVision AB (publ)?
The stock symbol or ticker of CellaVision AB (publ) is CLVSF.
Which industry does the CellaVision AB (publ) company belong to?
The CellaVision AB (publ) industry is Medical Devices.
How many shares does CellaVision AB (publ) have in circulation?
The max supply of CellaVision AB (publ) shares is 23.85M.
What is CellaVision AB (publ) Price to Earnings Ratio (PE Ratio)?
CellaVision AB (publ) PE Ratio is 22.11475400 now.
What was CellaVision AB (publ) earnings per share over the trailing 12 months (TTM)?
CellaVision AB (publ) EPS is 0.61 USD over the trailing 12 months.
Which sector does the CellaVision AB (publ) company belong to?
The CellaVision AB (publ) sector is Healthcare.


